Skip to main navigation
Skip to main content
KalVista logo

Main navigation

Investor Relations

  • About KalVista
    • Senior Management
    • Board of Directors
    • Contact Us
    • Careers
  • Products & Pipeline
    • Pipeline
    • KalVista for HAE
    • Sebetralstat
    • Factor XIIa
    • KalVista for DME
    • Publications
  • For Patients
    • HAE Patient Resources
    • Sebetralstat
    • Factor XIIa
    • DME Patient Resources
  • For Healthcare Providers
    • HAE Resources
    • Sebetralstat
    • Factor XIIa
    • DME Resources
    • Publications
    • Expanded Access
  • For Investors
    • Annual Meeting
    • Stock Information
    • News Releases
    • Event Calendar
    • Presentations
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
 

Investors

Investors Overview

Investor Relations

  • About KalVista
    • Senior Management
    • Board of Directors
    • Contact Us
    • Careers
  • Products & Pipeline
    • Pipeline
    • KalVista for HAE
    • Sebetralstat
    • Factor XIIa
    • KalVista for DME
    • Publications
  • For Patients
    • HAE Patient Resources
    • Sebetralstat
    • Factor XIIa
    • DME Patient Resources
  • For Healthcare Providers
    • HAE Resources
    • Sebetralstat
    • Factor XIIa
    • DME Resources
    • Publications
    • Expanded Access
  • For Investors
    • Annual Meeting
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • News Releases
    • Event Calendar
    • Presentations
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
 

Corporate Profile

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

All Stock Information
Latest News

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2023

KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

January 5, 2023

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 4, 2023
All News Releases
Featured Event

Jefferies Healthcare Conference

Jun 8, 2022 at 11:30 AM EDT
All Events
Presentations

Corporate Presentation January 2023

January 6, 2023
All Presentations

Main navigation

Investor Relations

  • About KalVista
    • Senior Management
    • Board of Directors
    • Contact Us
    • Careers
  • Products & Pipeline
    • Pipeline
    • KalVista for HAE
    • Sebetralstat
    • Factor XIIa
    • KalVista for DME
    • Publications
  • For Patients
    • HAE Patient Resources
    • Sebetralstat
    • Factor XIIa
    • DME Patient Resources
  • For Healthcare Providers
    • HAE Resources
    • Sebetralstat
    • Factor XIIa
    • DME Resources
    • Publications
    • Expanded Access
  • For Investors
    • Annual Meeting
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • News Releases
    • Event Calendar
    • Presentations
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance

Looking for SEC Filing Information?

Meet Our Board of Directors

shareholder-tools

Print Page
Print Page
Email Alerts
Email Alerts
RSS
RSS
IR Contacts
IR Contacts
Search
Search

Footer

Footer Nav

  • About KalVista
  • Products & Pipeline
  • For Patients
  • For Healthcare Providers
  • For Investors
  • Contact Us
+1 (857) 999 0075 info@kalvista.com

Social Menu

  • Linked In
  • Twitter
Copyright © 2023 | All rights reserved.

Footer Bottom

Footer Bottom

  • Kalvista Terms
  • Privacy